Bo Yan

ORCID: 0000-0002-5708-2460 · 7 papers in corpus
review 2026
International journal of women's health ·doi:10.2147/IJWH.S629329

In this narrative review, we summarize current evidence regarding the endometrium undergoes cyclic remodeling driven by estrogen (E2) and progesterone (P4) signaling, with precise coordination essential for receptivity and pregnancy establi…

review 2026

Zhiqiang Wang,1 Jinwei Yang,1 Bo Yan,2 Guangmei Xie11Reproductive Medicine Center, Gansu Provincial Maternity and Child-Care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, 730050, People’s Republic of China; 2Clinical Laborat…

review 2026
·doi:10.2147/ijwh.s629329

Abstract: In this narrative review, we summarize current evidence regarding the endometrium undergoes cyclic remodeling driven by estrogen (E2) and progesterone (P4) signaling, with precise coordination essential for receptivity and pregnan…

case-report 2026
Frontiers in medicine ·doi:10.3389/fmed.2026.1924149

BACKGROUND: Umbilical endometriosis is an uncommon form of extrapelvic endometriosis and may be misdiagnosed as other umbilical or urachal disorders. Cyclic umbilical bleeding or discharge is an important clinical clue, but the diagnosis is…

other 2024
Frontiers in endocrinology ·doi:10.3389/fendo.2024.1428147

BACKGROUND: Amphiregulin (AR) is a growth factor that resembles the epidermal growth factor (EGF) and serves various functions in different cells. However, no systematic studies or reports on the role of AR in human oocytes have currently b…

lab-animal 2023
Clinics (Sao Paulo, Brazil) ·doi:10.1016/j.clinsp.2023.100235

Recent studies have found that lncRNA-MEG3(MEG3) plays an important role in the development of EMs (Endometriosis), but the specific mechanism needs to be further explored. This study aimed to investigate the effect of MEG3 on the prolifera…

case-report 2021
·doi:10.31083/j.ceog.2021.02.2119

Rationale: Adenomyosis is a disease in which the endometrial tissues (glands and stroma) extend into the myometrium. It usually occurs in parous women aged 35 to 50 years old. The common symptoms include secondary severe dysmenorrhea and me…